A total of 37,72,000 shares will be offered through the Bio Medica Laboratories IPO. These shares have a nominal value of ₹10 each. A sum of ₹52 crore will be raised in this offering. The offer period opens on May 21, 2026. The applications will be accepted until the offer closes on May 25, 2026. The share allotment has been planned to take place on May 26, 2026. This IPO’s listing will happen on May 29, 2026, on the NSE SME.
The lot size is set at 1,000 shares with the price band ranging from ₹132 to ₹139. To participate in the retail segment, investors must place bids for a minimum of two lots worth ₹2,78,000. For sNII, the minimum bid size is three lots, which makes their investment ₹4,17,000. Participants from the bNII category will have an outlay of ₹11,12,000 for eight lots.
Bio Medica Laboratories IPO Details
This offering’s main particulars are listed below:
| Particulars | Details |
| Bidding Opens | May 21, 2026 |
| Bidding Closes | May 25, 2026 |
| Face Value | ₹10 per share |
| Issue Type | Bookbuilding Issue |
| Price Band | ₹132 to ₹139 |
| Issue Price | |
| Listing at | NSE SME |
| Lot Size | 1,000 Shares |
| Fresh Issue | 32,06,000 shares (₹45 Crore) |
| Reserved for Market Maker | 1,89,000 shares (₹3 Crore) |
| Offer for Sale (OFS) | 3,77,000 shares (₹5 Crore) |
| Total Issue | 37,72,000 shares (₹52 Crore) |
| Minimum Investment | ₹2,78,000 |
Bio Medica Laboratories IPO Timeline
The given table shows the schedule this IPO will follow:
| Particulars | Details |
| Bidding Opens | May 21, 2026 |
| Bidding Closes | May 25, 2026 |
| Allotment Expected | May 26, 2026 |
| Refunds Start On | May 27, 2026 |
| Share Credit to Demat | May 27, 2026 |
| Listing Scheduled | May 29, 2026 |
| Cut-off for UPI mandate | 5:00 PM on May 25, 2026 |
Bio Medica Laboratories Key Performance Indicators
The KPIs of Bio Medica Laboratories are presented in the table below:
| KPIs | FY25 | FY24 | FY23 |
| ROE (%) | 99.59 | 67.74 | 13.92 |
| ROCE (%) | 48.20 | 29.92 | 10.16 |
| Debt Equity (times) | 1.02 | 2.12 | 3.94 |
| RoNW (%) | 99.59 | 67.74 | 13.92 |
| PAT Margin (%) | 25.64 | 16.39 | 2.06 |
| EBITDA Margin (%) | 39.83 | 36.93 | 10.47 |
| Price Book Value | 8.66 | – | – |
Financials of Bio Medica Laboratories
Here is an overview of the financial metrics of Bio Medica Laboratories:
| Particulars (in ₹ lakh) | FY25 | FY24 | FY23 |
| Total Assets | 3,911.79 | 1,953.08 | 1,756.65 |
| Revenue | 3,832.50 | 1,534.42 | 1,624.96 |
| Profit | 979.49 | 249.87 | 33.35 |
Bio Medica Laboratories IPO Subscription Status
The subscription details of this offering are as follows:
| Date | QIB (Ex Anchor) | NII* | Individual Investors | Total |
|---|---|---|---|---|
| May 21 (Day 1) | 15.94 | 0.03 | 1.09 | 0.72 |
| May 22 (Day 2) | 15.94 | 0.28 | 1.42 | 1.01 |
Bio Medica Laboratories IPO Grey Market Premium
In the grey market, this IPO is trading at a premium of ₹4, indicating mild investor interest. Based on the prevailing trend, the shares will likely list at ₹143, giving 2.88% listing gains.
| GMP Date | GMP | Est. Listing Price | Est. Profit* | Last Updated |
|---|---|---|---|---|
| 22-05-2026 | ₹0 ▼ | ₹139 (0.00%) | ₹0 | 22-May-2026 20:59 |
| 21-05-2026 Open | ₹3.5 ▲ | ₹142.5 (2.52%) | ₹3,500 | 21-May-2026 23:33 |
| 20-05-2026 | ₹0 ─ | ₹139 (0.00%) | ₹0 | 20-May-2026 23:32 |
| 19-05-2026 | ₹0 ─ | ₹139 (0.00%) | ₹0 | 19-May-2026 23:36 |
| 18-05-2026 | ₹0 ─ | ₹139 (0.00%) | ₹0 | 18-May-2026 23:35 |
Note: GMP values come from unofficial transactions and are provided purely for reference. These figures may fluctuate depending on investor sentiment and market demand.
Bio Medica Laboratories IPO Reservation
The issue reserves separate portions for different classes of investors.
| Investor Category | Reservation |
| Market Maker Shares | 1,89,000 |
| QIB Shares | 36,000 |
| NII (HNI) Shares | 17,55,000 |
| Retail Shares | 17,92,000 |
| Total Shares | 37,72,000 |
Lot size of the Bio Medica Laboratories IPO
The following table presents the bid requirements for each investor category:
| Investor Type | Lots | Shares | Amount |
| Retail Investors – Minimum Bid | 2 | 2,000 | ₹2,78,000 |
| Retail Investors – Maximum Bid | 2 | 2,000 | ₹2,78,000 |
| S-HNI – Minimum Bid | 3 | 3,000 | ₹4,17,000 |
| S-HNI – Maximum Bid | 7 | 7,000 | ₹9,73,000 |
| B-HNI – Minimum Bid | 8 | 8,000 | ₹11,12,000 |
Bio Medica Laboratories IPO Anchor Investors
Given below are the anchor investor particulars of the offering:
| Particulars | Details |
| Anchor Bidding Opens | May 20, 2026 |
| Shares Offered | Not Disclosed Yet |
| Portion Size | 60% of the QIB portion |
| Lock-in for 50% Shares (30 Days) | June 25, 2026 |
| Remaining Shares Lock-in (90 Days) | August 24, 2026 |
Bio Medica Laboratories IPO Prospectus
Readers can explore the linked resources below to learn more about the offering.
| Draft Red Herring Prospectus (DRHP) | |
| Red Herring Prospectus (RHP) | |
| Anchor Investors | – |
| Final Prospectus | Not Disclosed Yet |
About Bio Medica Laboratories
Bio Medica Laboratories was founded in 2015 by promoters Pradeep Mehta and Mukesh Mehta. Out of the two, Pradeep Mehta serves as the Managing Director, overseeing the strategic direction and overall administration of the company. The firm operates in the pharmaceutical and healthcare segment. It manufactures generic injectable formulations, including dry powder and liquid injections. These products cater to humans as well as animal healthcare.
The firm runs on a B2B model. It produces formulations for other pharmaceutical companies on a contract basis. Its manufacturing and laboratory operations are backed by the Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certifications from the Food & Drugs Administration, Madhya Pradesh. Its in-house laboratory is equipped with advanced testing instruments for quality control, stability studies, and process validation across its operations.
| Lead Manager | Narnolia Financial Services |
| IPO Registrar | Skyline Financial Services |
Bio Medica Laboratories IPO Objectives
The funds generated through the issue are proposed to be used for the given purposes:
| S. No. | Particulars | Amount (in ₹ lakh) |
| 1. | Loan Repayment | 650.00 |
| 2. | New manufacturing unit setup | 2,850.00 |
| 3. | General corporate uses | – |
Strengths of Bio Medica Laboratories
Bio Medica Laboratories’ market standing is shaped by the following strengths:
- Experienced leadership team: The company is led by experienced promoters with over 37 years in the pharmaceutical industry, supported by a management team focused on operational efficiency and business growth.
- Quality assurance: The company follows strict quality standards through GMP and GLP-certified operations, supported by in-house testing facilities and a dedicated quality control team.
- Diversified product portfolio: The company manufactures 71 formulations across multiple categories, helping it cater to varied customer requirements and changing market demand more effectively.
- Established client relationships: The company has built long-term relationships with several customers, with some associations continuing for up to 10 years through repeat business and consistent service.
- Stable employee base: Bio Medica Laboratories has maintained relatively low employee attrition levels, reflecting workforce stability and its focus on employee growth, retention, and workplace continuity.
Risks of Bio Medica Laboratories
The following risks may influence Bio Medica Laboratories’ business performance and future outlook:
- Manufacturing and operational risks: Any product quality issue, contamination, or manufacturing defect could damage the company’s reputation and lead to legal or financial consequences.
- Exposure to regulatory inspections: The company’s manufacturing facilities are regularly inspected by regulatory authorities, and any adverse findings may impact operations, reputation, and financial performance.
- Reliance on third-party transportation: The company depends heavily on external logistics partners for raw material supply and product delivery, exposing operations to transport-related disruptions and delays.
- Technology upgradation challenges: Failure to adopt new technologies or upgrade manufacturing systems efficiently could impact competitiveness, operations, and business growth.
- Uncertainty in order book execution: Contracts in the order book may be delayed, modified, or cancelled by customers, making revenues less predictable.
Bio Medica Laboratories IPO Review
Bio Medica Laboratories IPO offers exposure to the growing pharmaceutical contract manufacturing segment, supported by improving financial performance, quality-certified operations, and a diversified formulation portfolio. At the same time, risks related to regulatory compliance, manufacturing, and dependence on third-party logistics should also be considered.
This offering may be more appropriate for investors prepared for the higher uncertainty typically seen in SME IPOs. Investors should carefully evaluate the company’s fundamentals and valuation before applying.
Other Recent IPO List
Explore newly launched IPOs and stay prepared for upcoming market offerings.
| M R Maniveni Foods IPO | Harikanta Overseas IPO |
| Vegorama Punjabi Angithi IPO | Teamtech Formwork Solutions IPO |
| NFP Sampoorna Foods IPO | Goldline Pharmaceutical IPO |
| RFBL Flexi Pack IPO | Simca Advertising IPO |
Bio Medica Laboratories IPO FAQs
Bio Medica Laboratories IPO is an NSE SME book building issue worth around ₹52 crore, comprising a fresh issue of ₹47 crore and an OFS of ₹5 crore.
Investors can apply through ASBA-supported bank accounts or UPI-enabled broker platforms by selecting the IPO and entering the desired lot quantity within the offer period.
The IPO shows improving financial performance and expansion plans, but investors should also consider regulatory, operational, and SME-related business risks before investing.
Based on the latest grey market trend, the IPO is indicating estimated listing gains of around 2.88%, though GMP is unofficial and can change.
The Bio Medica Laboratories IPO will open for subscription on May 21, 2026, and close on May 25, 2026.
The IPO lot size is 1,000 shares, while retail investors must apply for a minimum of 2 lots, amounting to ₹2,78,000.
The allotment for the Bio Medica Laboratories IPO is expected to be finalised on May 26, 2026.
Bio Medica Laboratories IPO is scheduled to list on the NSE SME platform on May 29, 2026.
